M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes Pharmaceutical TechnologyTerremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.M&A / DealsOncologyRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaceutical Technology Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity. M&A / DealsOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy studyNext: Most patients “won’t see benefit” with Alzheimer’s drugs Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
